2. Academic Validation
  3. Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction

Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction

  • Cell Insight. 2025 May 12;4(3):100251. doi: 10.1016/j.cellin.2025.100251.
Huajian Tian 1,  Guifei Li 1,  Cookson K C Chiu 2,  E Li 2,  Yuzong Chen 3 4,  Ting Zhu 4,  Min Hu 5,  Yanjie Wang 5,  Suping Wen 1,  Jiajia Li 1,  Shuangxue Luo 1,  Zhicheng Chen 1,  Huimei Zeng 1,  Nan Zheng 1,  Jinyong Wang 6 7,  Weijun Shen 1,  Xi Kang 1
Affiliations

Affiliations

  • 1 Translation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China.
  • 2 Multi-omics Mass Spectrometry Core, Biomedical Research Core Facilities, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China.
  • 3 Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China.
  • 4 The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, Guangdong, China.
  • 5 Genomics core, Biomedical Research Core Facilities, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China.
  • 6 Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China.
  • 7 Shenzhen International Institute for Biomedical Research, Shenzhen 518038, Guangdong, China.
PMID: 40547114 DOI: 10.1016/j.cellin.2025.100251
Abstract

While immune cell therapies have transformed Cancer treatment, achieving comparable success in solid tumors remains a significant challenge compared to hematologic malignancies like non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Over the past four decades, various immunotherapeutic strategies, including tumor vaccines, tumor-infiltrating lymphocyte (TIL) therapies, and T cell receptor (TCR) therapies, have demonstrated clinical efficacy in select solid tumors, suggesting potential advantages over CAR-T and CAR-NK cell therapies in specific contexts. The dynamic nature of the cancer-immunity cycle, characterized by the continuous evolution of tumor-specific neoantigens, enables tumors to evade immune surveillance. This highlights the urgent need for rapid and accurate identification of functional tumor neoantigens to inform the design of personalized tumor vaccines. These vaccines can be based on mRNA, dendritic cells (DCs), or synthetic peptides. In this study, we established a novel platform integrating immunoprecipitation-mass spectrometry (IP-MS) for efficient and direct identification of tumor-specific neoantigen peptides. By combining this approach with our proprietary AI-based prediction algorithm and high-throughput in vitro functional validation, we can generate patient-specific neoantigen candidates within six weeks, accelerating personalized tumor vaccine development.

Keywords

Mass spectrometry; Neoantigen; New algorithm; Tumor vaccine.

Figures
Products